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Introduction
Pneumocystis pneumonia (PCP) is a potentially life-
threatening fungal infection seen in
immunocompromised hosts. PCP was initially described
in humans in 1942, but was commonly reported with
human immunodeficiency virus (HIV) epidemic in the
United States in early 1980s. The main risk factors which
predispose to PCP infection include a variety of other
immune-deficient states such as haematological
malignancies, solid tumours, organ transplantations,
connective tissue diseases and use of
immunosuppressive medications such as corticosteroids
and chemotherapeutic agents.1-8 The mortality rate for
HIV-infected patients who develop PCP is around 10-
20% during the first episode of this infection. The death
rate may reach as high as 30-60% in non-HIV-infected
cases of PCP, with the highest risk of mortality seen in
cancer patients.3,9-11 PCP remains a diagnostic challenge
due to its non-specific signs and symptoms, the use of
prophylactic drugs which might alter the clinical
presentation and other opportunistic infections in an
immuno-suppressed patient.3
Infection with HIV and subsequent infection with PCP
has been studied in detail and PCP has been recognised
as one of the acquired immunodeficiency syndrome
(AIDS) defining conditions in HIV-positive individuals.
Autoimmune diseases also render individuals
susceptible to PCP, not only by disease pathophysiology
but also due to the immunosuppressive agents used for
treatment. Both haematological and solid organ
malignancies as well as transplant recipients also remain
vulnerable to PCP secondary to the same phenomenon.3
In Western countries, PCP is historically recognised as
the HIV-indicator disease.12 Clinical spectrum of PCP,
both in HIV and non-HIV population, from higher
income countries has been intricately researched and
well documented.13 On the other hand, low- and
middle-income countries (LMICs) have been previously
regarded as low PCP prevalent areas and limited data is
available about the trends and clinical outcomes of PCP
in resource-poor settings.13,14 Studies from India have
shown a low prevalence of PCP of 5-6% with mortality
rates as high as 29%.15,16 Pakistan is a low-income
country with an under-developed healthcare system. To
the best of our knowledge, we have been unable to find
data on PCP-related studies from this country. The
current study was planned to assess PCP outcome
among hospitalised patients, both in HIV and non-HIV
individuals in a large tertiary care hospital. We sought to
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Abstract
Objective: To assess the predisposing immunocompromised states, administration of pneumocystis jirovecii
pneumonia prophylaxis, the disease course and outcomes of patients with pneumocystis jirovecii pneumonia.
Methods: The retrospective study was conducted at the Aga Khan University Hospital in Karachi. Themedical records
of patients diagnosed with pneumocystis jirovecii pneumonia from January 1995 to October 2015 were retrieved.
Baseline characteristics, clinical course, treatment, andmortality rates were noted. SPSS 19 was used for data analysis.
Results: Of the 37 patients, 24(64.9%) were men and 13(35.1%) were women. The overall mean presenting age was
47.08±16.21 years (range: 19-83 years). Ten (27%) patients were positive for human immunodeficiency virus; 12(32.4%)
had an underlying autoimmune disease; 3(8.1%) were transplant recipients; 10(27%) had an underlying malignancy,
and 19(51.3%) were on long-term corticosteroid therapy. Only 2(5.4%) patients had received pneumocystis jirovecii
pneumonia prophylaxis with trimethoprim-sulfamethoxazole. Moreover, 8(21.6%) patients required intensive care unit
admission with a mean stay of 2.03±4.91 days (range: 1-22 days).The overall mortality rate was 7(18.9%).
Conclusion: Pneumonia due to pneumocystis jirovecii was found to be a life-threatening disease in the
immunocompromised population. The high mortality burden and resource intensive management of the disease
emphasizes the need for PCP prophylaxis in immunosuppressed individuals.
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define demographics, major predisposing
immunocompromised states, administration of PCP
prophylaxis and its impact, disease course, presence of
co-infection and clinical outcomes in patients affected
by PCP.
Materials and Methods
The retrospective study was conducted at the Aga Khan
University Hospital (AKUH), Karachi, and comprised
records of patients diagnosed with PCP from January
1995 to October 2015.
The AKUH is a 740-bed, private, tertiary-care hospital
which caters to the needs of over 50,000 patients
annually. Ethical approval was obtained from the
institutional review committee. Hospital records were
retrieved by accessing Health Information Management
Services (HIMS) in order to identify patients who had
received a discharge diagnosis of 'Pneumocystosis'.
Patients aged above 18 years who had a laboratory
confirmed diagnosis of PCP were included. Direct
immune fluorescent test (Bio-Rad, France) was performed
on sputum, broncho-alveolar lavage and lung tissue
specimens in the clinical microbiology laboratory.
Patients who had not undergone laboratory testing and
had received empirical therapy without laboratory
confirmation for PCP were excluded.
A data collection sheet was prepared in order to collect
information on demographics, pertinent past medical
history (comorbid conditions, immunocompromised
states and HIV status), and details regarding hospital
admission, presenting complaints, laboratory and
radiographic data, admission to the intensive care unit
(ICU), length of stay, treatment regimen, clinical outcome
and cause of death. Clinical charts were reviewed and
data was entered in EpiData version 6.0 (EpiData
Association, Odense, Denmark).
SPSS 19 was used for data analysis. Simple frequency and
descriptive analysis was run for patient demographic
characteristics aswell as for categorical variables, and cross-
tabulationwas carried out. Independent samples t-test was
run in order to evaluate for equality of means within HIV
versus non-HIV patients as well as for survivors versus non-
survivors and 95% confidence interval (CI) was calculated.
Results
Of the 112 cases identified, 37(33%) had been laboratory
confirmed for PCP. The remaining 75(66.96%) patients had
received empirical treatment for PCP along with other
likely causes of pneumonia as per the attending
physician's discretion without undergoing laboratory
testing for PCP.
The overall mean age was 47.08±16.21 years (range: 19-
83 years).Of the study population, 24(64.9%) were men
and 13(35.1%) were women. Besides, 10(27%) were HIV-
positive, 12(32.4%) had an underlying inflammatory
autoimmune condition, 3(8.1%) were transplant
recipients (2(66.67%) liver and 1(33.33%) renal),
10(27%) had an underlying malignancy, 19(51.3%) were
on long-term steroid therapy,9(24.3%) were receiving
an additional form of chemotherapy or immuno-
suppressants, and 3(8.1%) had received radiation
therapy. Only 2(5.4%) of the patients had received PCP
prophylaxis (Table-1).
The mean age of HIV-positive patients was 43.40±7.26
years and that of HIV-negative patients was 48.44±18.40
years. Moreover, 31(83.8%) participants had symptoms of
low-grade fever. PCP prophylaxis was given in 2(20%) of
the HIV-positive patients and none of the HIV-negative
immunocompromised patients.
Oral candidiasis was present in 4(10.8%) patients,
whereas 2(5.4%) had concomitant pulmonary
tuberculosis and 2(5.4%) had pulmonary nocardiosis.
The HIV-positive patients had a mean CD4 cell count of
15.64±9.6 (Table-2).
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Table-1: Demographics of study population (n=37).
Variables Number (%)
Age in years, (mean ±SD, range) 45.77±16.83, 19-83
Gender
Male 24 (64.9)
Female 13 (35.1)
Underlying immune-compromised disease
HIV-positive 10 (27.0)
Autoimmune disease (n=12)
Systemic Lupus Erythmatosus (SLE) 6 (16.2)
Membranous Nephropathy 2 (5.4)
Crescentric Glomerulonephritis 1 (2.7)
Polymyalgia Rheumatica 1 (2.7)
Autoimmune Haemolytic anaemia 1 (2.7)
Idiopathic Thrombocytopenic Purpura 1 (2.7)
Malignancy (n=10)
Solid Malignancy 7 (70.0)
Haematological Malignancy 3 (30.0)
Transplant Recipient (n=3)
Liver 2 (66.6)
Renal 1 (33.3)
Immuno-suppressant drugs (n=28)
Corticosteroids 19 (67.8)
Other immunosuppressive agents 9 (32.1)
(cyclophosphamide, methotrexate)
HIV: Human immunodeficiency virus
SD: Standard deviation.
Trimethoprim/Sulfamethoxazole (TMP-SMX) was used
in high doses to treat all cases and dose was adjusted
for creatinine clearance if required as per
international recommendations. The adjuvant steroid
therapy was given to 20(54%) patients due to
hypoxaemia. Besides, 8(21.6%) required ICU
admission due to either haemodynamic instability or
respiratory failure and 7(18.92%) expired in the ICU.
Average length of ICU stay was 2.03±4.91 days (range:
1-22days).
The overall mean hospital stay was 7.43±6.45 days (range:
1-34 days).The overall mortality rate was 7(18.9%), with
respiratory failure being the leading cause of death. The
mortality rate between HIV-positive and HIV-negative
patients was not significantly different (p=0.64).
Discussion
Our study showed that less than one-third of the HIV-
negative patients had haematological malignancies
and transplants, while almost half of the patients
suffered from autoimmune inflammatory diseases.
These findings were similar to those shown by
Matsumura et al.17 In our study, there was a smaller
proportion of transplant patients while those had
undergone transplants usually received prophylaxis,
therefore, contributing towards a smaller number of
patients with PCP. Previous studies have shown that
infection of PCP in HIV-negative patients not receiving
prophylaxis is highest in haematological malignancies
and transplantation.8,18 This study showed that low-
grade fever was the most common symptom at
presentation for PCP.HIV-positive patients presented
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Table-2: Clinical characteristics of patients with Pneumocystis jirovecii pneumonia (PCP).
Clinical characteristics All patients (n=37) HIV-positive (n=10, 27.0%) HIV-negative (n=27, 73.0%) p-value
Gender 0.44
Male 24 (64.9) 8 (80) 16 (59.3)
Female 13 (35.1) 2 (20) 11 (40.7)
Mean age ± SD (years) 47.08±16.21 43.4±7.2 48.4±18.4 0.4
Age category
< 25 years 2 (5.4) 0 (0) 2 (7.4)
25-39 years 10 (27) 4 (40.0) 6 (22.2) 0.2
40-64 years 18(48.6) 6 (60.0) 12 (44.4)
> 65 years 7 (18.9) 0 (0) 7 (25.9)
PCP prophylaxis
Yes 2 (5.4) 2 (20.0) 0 (0)
No 35 (94.5) 8 (80.0) 27 (100) 0.06
Duration of symptoms (days) 25.5±65.2 61.8±114.8 10.0±6.4 0.044
Symptoms
Fever 31 (83.8) 10 (100) 21 (77.8) 0.16
Dyspnoea 21 (56.8) 4 (40.0) 17 (68.0) 0.15
Cough 25 (67.6) 10 (100) 15 (62.5) 0.03
Laboratory findings
Haemoglobin g/dl 11.1±2.5 10.9±2.4 11.2±2.57 0.79
WBC /x103mm3 6.7±5.7 5.6±2.8 7.04±6.32 0.86*
Neutrophils/mm3 79.08±11.26 77.5±12.4 79.5±11.09 0.64
Lymphocytes/mm3 15.56±10.47 15.6±9.2 15.5±10.9 0.72*
Platelets/mm3 206.08±121.29 195.6±119 209.9±126.2 0.82*
ICU admission & mechanical ventilation 8 (21.6) 1 (10) 7 (25.9) 0.4
Complications
Pneumothorax 3 (8.1) 1 (11.1) 2 (18.2) 0.99
Septic Shock 1 (2.7) 0 (0) 1 (9.1) 0.99
Respiratory failure 7 (23.3) 1 (11.1) 6 (28.6) 0.24
Average length of ICU stay (days) 2.03±4.91 0.50±1.58 2.62±5.62 0.25
Average length of hospital stay (days) 7.43±6.45 8±3.7 7.22±7.25 0.75
Overall outcome
Recovered 30 (81) 9 (90) 18 (66.7) 0.22
Expired 7 (18.9) 1 (10) 9 (90) 0.64
*Mann-Whitney U-test.
with symptoms like fever, cough and dyspnoea more
often than HIV-negative patients. However, this
finding failed to reach statistical significance. Lowe et
al. conducted a meta-analysis to assess PCP status in
LMICs.14 Some of their findings concluded that the
predictive value of signs, symptoms and simple
diagnostic tests was poor, and case fatality rates were
as high as 30%.14
Overall, a small number of patients were laboratory
tested for PCP in our setting. This may be misleading
and reflect an overall low frequency of PCP. However, it
should be noted that a total of 112 cases were initially
identified from hospital records who had received the
diagnostic International Classification of Disease (ICD)
code of PCP. A large number of these cases were
excluded as they had not undergone laboratory testing
and had received empirical treatment for pneumonia
along with PCP. Some of the reasons for not using
diagnostic studies such as bronchoalveolar lavage and
laboratory tests for these patients were cost constraints,
refusal to undergo invasive testing and risk of
intubation during the procedure. It has been reported
previously that the use of available gold standard
diagnostic cytological examination of respiratory
samples is low and hence affects reported prevalence
rates.14
In this study, mortality in HIV-negative patients was
twice that of HIV-positive patients. This is in accordance
with previous studies which have shown that HIV-
negative status is known to be associated with an
increased mortality in PCP infection when compared to
HIV-positive patients.8,14,19-22 Since PCP in non-HIV
population has a higher mortality rate than in HIV-
positive individuals, a rigorous prophylactic regimen is
needed. Our study showed that a very small proportion
of patients received prophylaxis and were therefore
susceptible to PCP.
We also observed that a relatively younger population
was affected by PCP and male predominance was
obvious. However, HIV-negative patients had an overall
mean age greater than that of HIV-positive patients.
Similar findings were demonstrated in a previous study.23
Male predominance has been demonstrated in HIV-
positive patients affected by PCP.23
The main limitation of our study is the small number of
patients who were laboratory-confirmed for PCP. Another
limitation is that our study did not take into account
controls that might have received prophylaxis and had
consequently not suffered from PCP.
Conclusion
Pneumonia due to pneumocystis jiroveciiwas found to be
a life-threatening disease in the immunocompromised
population. Given the high mortality burden and
resource-intensive management of PCP, attention needs
to be called towards instituting a rigorous prophylactic
regimen in all type of immunosuppressed patients.
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